ImmVirX

Receptor Targeted Oncolytic Viruses

Bell Potter Healthcare Conference

November 11 2021

Disclaimer

This presentation comprises general information only. This presentation shall not be construed as a prospectus or an offer to sell or issue, or a solicitation of an offer to buy, any security in any jurisdiction.
THIS PRESENTATION MAY NOT BE COPIED OR REPRODUCED IN ANY FORM, FURTHER DISTRIBUTED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE, IN PARTICULAR THIS PRESENTATION AND ITS CONTENTS ARE STRICTLY CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND DEPENDENCIES, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR TO ANY RESIDENT THEREOF, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL.

Disclaimer

This presentation has been prepared by ImmVirx Pty Ltd (ACN 634 890 761) (**ImmVirX**) to provide summary information about ImmVirX and certain plans and objectives of ImmVirX. The information in this presentation is of a general nature and does not purport to be complete, is provided solely for information purposes and should not be relied upon by any person. No representation or warranty, express or implied, is made by any person as to the fairness, accuracy, completeness or correctness of the information contained in this presentation. This presentation does not purport to summarise all information that a person should consider when making any decision to enter into any transaction with ImmVirX or any other party, and should not form the basis of any decision by a person.

Reliance should not be placed on the information or opinions contained in this presentation, and it is subject to change. This presentation is for informational purposes only and is not financial product or investment advice, or a recommendation or invitation to enter into any transaction with ImmVirX or any other party, or a representation that ImmVirX or any other party will be entering into any transaction. This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular person. Each recipient should conduct their own investigations of any transaction with ImmVirX or any other applicable party, as well as analysis of the financial condition, assets and liabilities, financial position and performance, profits and losses, prospects and business affairs of ImmVirX and its business, and the contents of this presentation. Recipients should seek their own legal, financial, tax and other professional advice in connection with any transaction with ImmVirX or any other party.

ImmVirX assumes no liability

To the maximum extent permitted by law, none of ImmVirX nor any of its subsidiaries, affiliates and related bodies corporate, nor any of their respective officers, directors, employees, advisers and agents (**Related Parties**), nor any other person, accepts any responsibility or liability for, and makes no recommendation, representation or warranty concerning the content of this presentation, ImmVirX or any securities or any transaction that ImmVirX or other applicable party may enter into including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of, or reliance on, any of the information contained in this presentation or otherwise arising in connection with it. To the maximum extent permitted by law, ImmVirX, each of its subsidiaries and each of their Related Parties disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

This presentation is strictly confidential

This presentation is confidential and not for further distribution. It is provided on the basis that, by accepting this presentation, persons to whom this presentation is given agree to keep the information confidential, not copy the presentation and not to disclose it, in whole or in part, to anyone except to their professional advisers on a need-to-know basis and subject to the same confidentiality restrictions as set out above.

Past and future performance

Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

This presentation contains certain forward-looking statements, including with respect to the financial condition, operations and business of ImmVirX and certain plans and objectives of ImmVirX. Such forward looking statements involve known and unknown risks, uncertainties and other factors that because of their nature may cause the actual results, performance or actions of ImmVirX, or any other party, to be materially different from the results, performance or actions expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding ImmVirX's present and future business strategies and the political and economic environment in which ImmVirX will operate in the future, which may not be reasonable, and are not guarantees or predictions of future performance. No representation is made that any of these statements or forecasts will come to pass or that any forecast result will be achieved, or that there is a reasonable basis for any of these statements or forecasts.

Reservation of rights

Neither of ImmVirX nor any other party has committed to entering into any transaction and, and to the extent permitted by law or regulatory code, it reserves all rights in relation to the conduct of any transaction, including without limitation: (1) the right to negotiate with one or more prospective parties at any time; (2) to enter into binding documentation in relation to any transaction; (3) provide or not to provide additional information and to provide differential information to different parties; (4) to withdraw from discussions; or (5) to vary (in whole or in part) or terminate any transaction, at any time without notice or reasons to any party.

Restrictions

The distribution of this presentation or any information contained in it, and the offering or sale of securities may be restricted by law in certain jurisdictions, and therefore any person into whose possession any document containing this presentation or any part of it comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions could result in a violation of the laws of such jurisdiction. Recipients of this presentation are required to inform themselves of, and comply with, all such restrictions or prohibitions and neither ImmVirX nor any other person accepts any liability to any person in relation thereto.

The securities of ImmVirX have not been and will not be registered under the US Securities Act of 1933, as amended (**US Securities Act**). There will be no public offering of the ImmVirX's securities in the United States. The securities will be offered and sold solely (a) in the United States to investors that are (i) a "qualified institutional buyer" (**QIB**) as defined in Rule 144A under the US Securities Act or (ii) a dealer or other professional fiduciary organized, incorporated or (if an individual) resident in the United States that is acting solely for a discretionary or similar account (other than an estate or trust) held for the benefit or account of a person that is not a U.S. Person (as such term is defined in Rule 902(k) under the US Securities Act) for which it has sole investment discretion (**Eligible U.S. Fund Manager**); or (b), outside the United States in "offshore transactions" in reliance on Regulation S. Any failure to comply with this restriction may constitute a violation of United States securities laws.

Agreement

By accepting receipt of or electronically accessing this presentation or attending any presentation or delivery of this presentation you agree to be bound by the foregoing limitations and conditions and, in particular, will be taken to have represented, warranted, undertaken and acknowledged to ImmVirX that: (i) you are able to receive this presentation without contravention of any applicable legal or regulatory restrictions; (ii) if you are in Australia, you are either a professional investor or sophisticated investor (as those terms are defined by section 708(8) and (11) of the *Corporations Act 2001* (Cth); (iii) you are not located in the United States and will not transmit or send any information contained in this presentation to any other persons in the United States or to any publications with a general circulation in the United States, or, if you are located in the United States, you are a QIB or an Eligible US Fund Manager; (iv) you will not rely on this presentation for the purposes of any involvement in any offering of ImmVirX's securities; and (v) you will not record, distribute, copy, reproduce, publish, store in a retrieval system, transmit or pass on this presentation, directly or indirectly, in whole or in part.

Successful Track Record in Oncolytic Immunotherapy

Dr. Malcolm McColl
CEO and Co-Founder
Viralytics
CSL Hospira

Prof. Darren Shafren
CSO and Co-Founder
Viralytics
The University of Newcastle Australia

Robert Vickery
CFO
Viralytics

Dr. Leonard Post
Non-Executive Director
Viralytics
Vivace therapeutics BIOMARIN

Robert Routley
Non-Executive Director
Acorn Capital Next Generation Investing

Dr. Jennifer Rosenthal
Director Quality & Regulatory Affairs
Viralytics
Alchemia

Cohesive Team Leveraging Viralytics Experience

- Leadership and scientific team comprised of ex-Viralytics team members responsible for invention, preclinical and clinical development of CAVATAK technology through to acquisition by Merck for $A502M
- Deep regulatory knowledge with extensive interactions with FDA
- GMP manufacturing and quality systems experience
- Global networks of clinicians and KOLs to facilitate clinical programs
- R&D team in ex-Viralytics facility at TUNRA/University of Newcastle Hunter Medical Research Institute
- Recently completed Series A-1 financing raising $25M to provide runway to mid 2023

Oncolytic Viruses: Expanding the Reach and Impact of Immunotherapy

- Immunotherapies including checkpoint inhibitors have been transformative, but only for a subset of patients
- Despite limitations, the cancer immunotherapy market is projected to reach USD$125B by 2024*

Oncolytic virus immunotherapies are an emerging class of combination therapy agents with the potential to **expand the reach** of immunotherapy to **indications not currently responsive** to checkpoint inhibitors

Validating high value oncolytic virus transactions and valuations

Amgen acquisition of Biovex

USD$425M cash upfront, USD$575M future milestone payments

Merck acquisition of Viralytics

A$502M cash upfront

Replimune Valuation

Pre-IND IPO at USD$462M valuation, current market cap ~ USD$1.6B

Oncorus Valuation

Early clinical stage, IPO October 2020, current market cap ~ USD$300M

* Transparency Market Research, April 15, 2019 (http://www.transparencymarketresearch.com)

ImmVirX Targeting Substantial Markets with High Unmet Need

Indication	Incidence		Clinical Response	
	USA[1]	China[3]	ICI ORR[4]	Study Identifier
Ovarian	21,750	52,971	9% KEYTRUDA	KEYNOTE-100
Colorectal[2]	147,950	521,490	4% KEYTRUDA	KEYNOTE-028
Gastric	27,600	392,868	17% KEYTRUDA	KEYNOTE-224
Pancreatic	57,600	116,291		

[1] Cancer Facts and Figures 2020, American Cancer Society, 2019
[2] Includes all types of colorectal cancer (CRC). ImmVirX focus in on MMRp (Mismatch Repair Proficient) accounting for ~94% of all CRC (Dung et al., Science, 2017; 357 (6349):409-413).
[3] WHI Globocan 2018 – China Factsheet
[4] ICI ORR = Immune Checkpoint Inhibitor Overall Response Rate

ImmVirX: Receptor Targeted Oncolytic Virus Entering the Clinic mid-2022

Platform

- Proprietary bioselection platform for receptor targeted oncolytic RNA viruses
- Selection for extracellular receptor targeting drives exquisite selectivity and potency in specific tumor types
- Oncolytic potency enables development of non-genetically modified virus with potential for future “armed” virus to express key immune stimulatory molecules

Proven Mechanism

- RNA virus drives tumor inflammation and immune cell infiltration via RIG-I pathway activation
- De-risked through preclinical in vitro and in vivo proof-of-concept, replicating CAVATAK’s oncolytic activity and molecular mechanism

Clinical Strategy

- Virus specificity enables targeted approach in indications with high unmet needs including ovarian, CRC, gastric and pancreatic cancer
- Planned combination therapy with immune checkpoint inhibitors in indications with poor response rates to readily detect signals of activity
- Clear clinical development pathway with trial initiation expected mid-2022

IVX-037

Lead Candidate
Receptor Targeted
RNA Oncolytic Virus

Measuring In Vivo Oncolytic Activity of IVX-037

Human MSS colorectal cancer (WiDr) xenograft model

Day 0

Implant human WiDr cells into left flank



SCID Balb/C

Day 14

Single intratumoral treatment with IVX-037 or vehicle

IVX-037
or vehicle i.t

Day 33

Monitor for tumor burden and treatment tolerance



Monitor

IVX-037: Demonstrated In Vivo Oncolytic Activity

Human MSS colorectal cancer (WiDr) xenograft model







Striking reduction in tumor volume achieved in immune deficient mice provides clear signal of potency solely attributed to oncolytic activity of IVX-037 with favorable tolerability

Potency Observed Across Dose Levels

Dose escalation in human MSS colorectal cancer (WiDr) xenograft model



IVX-037 potency enables robust antitumor activity at a 10,000-fold lower dose

IVX-037: Demonstrated In Vivo Oncolytic Activity

Human MSS colorectal cancer (Caco-2) xenograft model







Activity of single dose of IVX-037 confirmed in a second model of colorectal cancer

IVX-037: Demonstrated In Vivo Oncolytic Activity

Human Gastric cancer (NCI-N87) xenograft model







Activity of single dose of IVX-037 also demonstrated in gastric cancer with favorable tolerability

IVX-037: Demonstrated In Vivo Oncolytic Activity

Human ovarian cancer (IGROV-1) xenograft model





Striking reduction in tumor volume provides clear signal of potency solely attributed to oncolytic activity of single dose of IVX-037 with favorable tolerability

IVX-037: Demonstrated In Vivo Oncolytic Activity

Human ovarian cancer (OVSAHO) xenograft model







Oncolytic activity of single dose of IVX-037 confirmed in a second model of ovarian cancer

Measuring In Vivo Oncolytic Activity of IVX-037

Human MSS colorectal cancer (WiDr) xenograft model – intravenous delivery



IVX-037: Demonstrated In Vivo Oncolytic Activity

Human MSS colorectal cancer (WiDr) xenograft model – intravenous delivery







Intravenous delivery of IVX037 achievable in colorectal xenograft. Evidence of impressive antitumour efficacy and no treatment related toxicity observed

ImmVirX: Impressive Progress since May 2021 Financing

Preclinical / IP

- Further xenografts completed with excellent results across CRC, gastric and ovarian cancer
- Targeted small animal model supply from the US to Australia for preclinical toxicology studies
- Different routes of administration including IV delivery in CRC and ovarian cancer underway
- Further findings regarding IVX037 receptor usage strengthens support for patent filings

CMC / Quality

- Master virus seed prepared at FDA approved GMP facility
- Logistics and documentation in readiness for IVX037 production including fill / finish for FIP study
- Contract completed with US GMP facility for production of clinical batches of drug product for US and Australian trials
- Viral formulation with potential for improved cold chain shipping and storage

Clinical

- Clinical Trial Protocol in development for phase 1a and 1b basket study
- Australian KOLs identified to lead and participate in the phase 1 study
- Short list of CROs identified with review and selection underway

Strengthened ImmVirX with 5 new hires across preclinical, CMC and clinical teams

Upcoming Milestones – through to Q3 2022

Preclinical / IP

- IV preclinical studies complete
- Preclinical toxicology complete
- Preclinical assessment in further indications
- Preclinical studies assessing IVX037 in combination with immune checkpoint inhibitors and CAR T-cell therapy

CMC / Quality

- Complete production at Australian sites for FIP studies
- Tech transfer to USA and engineering run and first GMP batch

Clinical

- Appoint CRO
- Ethics application for Australian Clinical Trial Sites
- Establish Australian Clinical Trial Sites
- Ethics and TGA approvals to commence phase 1 study
- First patient on trial
- Planning for US FDA IND filing

Advancing the Next Generation of Oncolytic Viruses



ImmVirX

Receptor Targeted Oncolytic Viruses

Thank You

Malcolm McColl
Chief Executive Officer and Co-Founder
malcolm.mccoll@immvirx.com